Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | c/o SanguiBioTech GmbH c/o HRH GmbH, Bleichenbruecke 9 HAMBURG 20354 |
Tel: | N/A |
Website: | www.sanguibiotech.com |
IR: | See website |
Key People | ||
Thomas Striepe Chief Executive Officer, Chief Financial Officer, Director |
Business Overview |
Sangui Biotech International, Inc. focuses on the development of pharmaceutical, medical and cosmetic products. The Company develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). It is engaged in seeking to market and selling its products through partnerships with industry partners across the world. It focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. It focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. It offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin. |
Financial Overview |
For the nine months ended 31 March 2023, Sangui Biotech International Inc revenues increased 20% to $70K. Net loss increased from $52K to $117K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Gain (Loss) on foreign exchange decrease from $56K (income) to $35K (expense), Interest expense increase of 10% to $15K (expense). |
Employees: | 1 as of Jun 30, 2013 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $1.09M as of Mar 31, 2023 |
Annual revenue (TTM): | $0.08M as of Mar 31, 2023 |
EBITDA (TTM): | -$0.11M as of Mar 31, 2023 |
Net annual income (TTM): | -$0.12M as of Mar 31, 2023 |
Free cash flow (TTM): | -$0.06M as of Mar 31, 2023 |
Net Debt Last Fiscal Year: | $0.78M as of Mar 31, 2023 |
Shares outstanding: | 209,901,842 as of May 12, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |